MedTrace Logo

Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)

NCT00723645 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 279

Last updated 2015-11-30

Study results available
· View outcomes & findings →

Summary

This is an observational, multicenter, nationwide study where information will be collected on the follow-up of participants with chronic hepatitis C virus (HCV) who have a viral response at the end of treatment with pegylated interferon alfa-2b (PEG IFN alfa-2b) plus ribavirin (RBV) administered according to the directions on the products' labeling. No administration of treatment is planned as a result of study enrollment.

Conditions

  • Hepatitis C, Chronic

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2010-04-30
Completion
2011-02-28

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00723645 on ClinicalTrials.gov